vector. The company’s lead gene therapy, BV-702, is AAV-based and is in preclinical development for Alzheimer’s disease. It improved cognition and calculated biological age (telomere length ...

Nearly 600,000 Americans are diagnosed with either Alzheimer's or Parkinson's each ... to truly test the effectiveness of the new viral vector treatment. 'Doing research in space is not something ...